XNAS
AUPH
Market cap1.20bUSD
Jul 16, Last price
8.85USD
1D
-1.56%
1Q
14.19%
Jan 2017
321.43%
IPO
-92.78%
Name
Aurinia Pharmaceuticals Inc
Chart & Performance
Profile
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 235,133 33.97% | 175,513 30.95% | 134,030 193.89% | |||||||
Cost of revenue | 221,061 | 258,825 | 247,023 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 14,072 | (83,312) | (112,993) | |||||||
NOPBT Margin | 5.98% | |||||||||
Operating Taxes | 1,696 | 551 | 1,828 | |||||||
Tax Rate | 12.05% | |||||||||
NOPAT | 12,376 | (83,863) | (114,821) | |||||||
Net income | 5,752 -107.37% | (78,020) -27.88% | (108,180) -40.22% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (40,239) | 2,433 | ||||||||
BB yield | 3.07% | -0.40% | ||||||||
Debt | ||||||||||
Debt current | 15,072 | 31,196 | 936 | |||||||
Long-term debt | 143,666 | 179,616 | 15,240 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 11,107 | 10,911 | 12,166 | |||||||
Net debt | (199,738) | (139,878) | (373,214) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 44,388 | (33,461) | (79,529) | |||||||
CAPEX | (281) | (718) | (292) | |||||||
Cash from investing activities | 39,262 | (6,706) | (60,632) | |||||||
Cash from financing activities | (49,092) | (5,130) | 2,433 | |||||||
FCF | 53,629 | (220,859) | (113,577) | |||||||
Balance | ||||||||||
Cash | 358,476 | 350,489 | 389,390 | |||||||
Long term investments | 201 | |||||||||
Excess cash | 346,719 | 341,914 | 382,688 | |||||||
Stockholders' equity | 250,479 | 257,166 | 319,946 | |||||||
Invested Capital | 217,475 | 244,904 | 105,118 | |||||||
ROIC | 5.35% | |||||||||
ROCE | 3.01% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 146,194 | 143,236 | 141,915 | |||||||
Price | 8.98 -0.11% | 8.99 108.10% | 4.32 -81.11% | |||||||
Market cap | 1,312,822 1.95% | 1,287,692 110.04% | 613,073 -79.28% | |||||||
EV | 1,113,084 | 1,147,814 | 239,859 | |||||||
EBITDA | 20,786 | (71,665) | (110,287) | |||||||
EV/EBITDA | 53.55 | |||||||||
Interest | 4,835 | 2,775 | 5,118 | |||||||
Interest/NOPBT | 34.36% |